[go: up one dir, main page]

MX2018005256A - Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion. - Google Patents

Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.

Info

Publication number
MX2018005256A
MX2018005256A MX2018005256A MX2018005256A MX2018005256A MX 2018005256 A MX2018005256 A MX 2018005256A MX 2018005256 A MX2018005256 A MX 2018005256A MX 2018005256 A MX2018005256 A MX 2018005256A MX 2018005256 A MX2018005256 A MX 2018005256A
Authority
MX
Mexico
Prior art keywords
botulinum toxin
methods
therapeutic
long duration
toxin formulations
Prior art date
Application number
MX2018005256A
Other languages
English (en)
Inventor
M Waugh Jacob
L Ruegg Curtis
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58630886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018005256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of MX2018005256A publication Critical patent/MX2018005256A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Esta invención provee composiciones inyectables novedosas que comprenden toxina botulínica que se le pueden administrar a un sujeto para varios fines terapéuticos estéticos y/o cosméticos. Las composiciones inyectables abarcadas por la invención exhiben una o más ventajas sobre las formulaciones convencionales de toxina botulínica, que incluyen antigenicidad reducida, tendencia reducida a experimentar difusión localizada indeseable después de la inyección, mayor duración de la eficacia clínica o mayor potencia relativa, inicio más rápido de la eficacia clínica y/o estabilidad mejorada. De acuerdo con la invención, un solo tratamiento por inyección de las composiciones produce respuestas clínicas significativas y una duración de efecto de por lo menos 6 meses en un sujeto sometido al tratamiento, como es provisto por los métodos de tratamiento descritos.
MX2018005256A 2015-10-29 2016-10-28 Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion. MX2018005256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248255P 2015-10-29 2015-10-29
PCT/US2016/059492 WO2017075468A1 (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Publications (1)

Publication Number Publication Date
MX2018005256A true MX2018005256A (es) 2019-09-04

Family

ID=58630886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005256A MX2018005256A (es) 2015-10-29 2016-10-28 Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.

Country Status (16)

Country Link
US (2) US20180311333A1 (es)
EP (1) EP3368071B1 (es)
JP (2) JP6955491B2 (es)
KR (1) KR102794108B1 (es)
CN (1) CN109069608A (es)
AU (2) AU2016343748A1 (es)
BR (1) BR112018008684A2 (es)
CA (1) CA3003447A1 (es)
CO (1) CO2018005361A2 (es)
DK (1) DK3368071T3 (es)
ES (1) ES2907652T3 (es)
IL (2) IL259016A (es)
MX (1) MX2018005256A (es)
RU (1) RU2018119765A (es)
SG (2) SG11201803566TA (es)
WO (1) WO2017075468A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
ES2688065T5 (es) * 2009-10-21 2024-10-04 Revance Therapeutics Inc Métodos y sistemas para purificar la neurotoxina botulínica no complejada
KR102794108B1 (ko) 2015-10-29 2025-04-11 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
RU2019141383A (ru) * 2017-05-18 2021-06-18 Реванс Терапьютикс, Инк. (Revance Therapeutics, Inc.) Способы лечения цервикальной дистонии
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
US12161703B2 (en) 2017-08-28 2024-12-10 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
US20200390871A1 (en) * 2017-11-03 2020-12-17 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
KR20210057106A (ko) * 2018-09-13 2021-05-20 알레간 인코포레이티드 교근 비대의 치료 방법
KR20220008311A (ko) * 2019-05-14 2022-01-20 에이리온 테라퓨틱스, 인코포레이티드 최대 효과 지연 및/또는 반응 지속시간 연장
KR20220155351A (ko) * 2020-03-18 2022-11-22 레반스 테라퓨틱스, 아이엔씨. 두통 치료를 위한 주사용 보툴리눔 독소 방법
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
EP4228599A4 (en) * 2020-10-13 2025-03-12 ReVance Therapeutics, Inc. METHODS FOR TREATMENT OF CERVICAL DYSTONIA
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
EP4294519A4 (en) * 2021-02-21 2025-01-22 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
WO2022228443A1 (en) * 2021-04-26 2022-11-03 Shanghaitech University Intramuscular compositions of botulinum neurotoxins
KR20230071072A (ko) * 2021-11-15 2023-05-23 (주)메디톡스 보툴리눔 독소 조성물
KR20230171400A (ko) * 2022-06-10 2023-12-20 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025064729A1 (en) * 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
NZ520201A (en) 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0923731B1 (pt) 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US20140154237A1 (en) * 2011-01-07 2014-06-05 Revance Therapeutics, Inc. Methods and kits for topical application, removal, and inactivation of therapeutic or cosmetic toxin compositions
EP2841095A4 (en) * 2012-03-22 2016-01-13 Revance Therapeutics Inc METHOD FOR THE TREATMENT OF WRINKLES WITH CHEMOSTENERVATING TOPICAL ACTIVE SUBSTANCES
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
KR102794108B1 (ko) 2015-10-29 2025-04-11 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법

Also Published As

Publication number Publication date
WO2017075468A1 (en) 2017-05-04
US20180311333A1 (en) 2018-11-01
CA3003447A1 (en) 2017-05-04
BR112018008684A2 (pt) 2018-11-27
EP3368071B1 (en) 2022-01-26
SG10202004337WA (en) 2020-06-29
JP2018531984A (ja) 2018-11-01
JP6955491B2 (ja) 2021-10-27
AU2023241373A1 (en) 2023-10-26
SG11201803566TA (en) 2018-05-30
KR102794108B1 (ko) 2025-04-11
CO2018005361A2 (es) 2018-10-10
IL286472A (en) 2021-10-31
KR20180077202A (ko) 2018-07-06
JP2022008814A (ja) 2022-01-14
EP3368071A1 (en) 2018-09-05
CN109069608A (zh) 2018-12-21
EP3368071A4 (en) 2019-05-29
RU2018119765A (ru) 2019-12-02
ES2907652T3 (es) 2022-04-25
DK3368071T3 (da) 2022-05-02
NZ742018A (en) 2024-07-05
IL259016A (en) 2018-06-28
RU2018119765A3 (es) 2020-03-17
US20220062400A1 (en) 2022-03-03
AU2016343748A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2018005256A (es) Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
AU2018253620A1 (en) Injectable botulinum toxin formulations
MX2025009223A (es) Agentes de union a clec9a y su uso
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12018502634A1 (en) Topical compositions of apremilast
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
MY188139A (en) Sodium channel modulators for the treatment of pain
SG10201907660YA (en) Use of short chain fatty acids in cancer prevention
WO2017194782A3 (en) Therapeutic targeting of non-cellular structures
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
NZ728796A (en) Aqueous formulation comprising paracetamol and ibuprofen
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
BR112017023762A2 (pt) formulações de depósito injetáveis
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.